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While in vitro studies had shown that fibroblast growth factor 2 (FGF2) can induce cell death in Ewing tumours, it remained unclear
how Ewing tumour cells survive in vivo within a FGF2-rich microenvironment. Serum- and integrin-mediated survival signals were,
therefore, studied in adherent monolayer and anchorage-independent colony cell cultures. In a panel of Ewing tumour cell lines,
either adhesion to collagen or exposure to serum alone only had a minor protective effect against FGF2. However, both combined
led to complete resistance to 5ngml
 1 FGF2 in three of four FGF2-sensitive cell lines (RD-ES, RM-82 and WE-68), and to an
increased survival as compared to other culture conditions in TC-71 cells. Inhibition studies with LY294002 demonstrated that the
serum signal is mediated via the phosphoinositide 3-OH kinase/AKT pathway. Thus, Ewing tumour cells escape FGF2-induced cell
death by modulating FGF2 signalling. The tumour microenvironment provides the necessary survival signals by integrin-mediated
adhesion and soluble serum factor(s). These survival signals warrant further investigation as a potential resistance mechanism to other
apoptosis-inducing agents in vivo.
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The molecular hallmark of the diverse group of Ewing tumours are
chromosomal translocations leading to the fusion of the EWS gene
on chromosome 22 with different members of the ETS family of
transcription factors (de Alava and Gerald, 2000). The EWS/ETS
fusion proteins appear (i) to act as abnormal transcription factors
regulating a network of target genes (e.g., manic fringe, PDGF-C,
TGFbII receptor) (Arvand and Denny, 2001) and (ii) to influence
post-transcriptional gene processing by interacting with compo-
nents of the cellular splicing machinery (e.g., TASR, SF1 and U1C)
(Knoop and Baker, 2001). Both effects are thought to be important
for the formation of the malignant phenotype. Despite the progress
in unravelling the molecular biology of this tumour entity, the
exact mechanisms that govern growth and survival of Ewing
tumours in vivo are still poorly understood.
Fibroblast growth factor (FGF2) (formerly: basic fibroblast
growth factor (bFGF)) is a classical growth and differentiation
factor that is ubiquitously expressed and belongs to a family of
heparin-binding, single-chain polypeptides. It is present in the
extracellular matrix where it is bound to heparan sulphate
proteoglycan. It influences a variety of biological processes including
cell growth and differentiation and angiogenesis. High levels of FGF2
activity in tumour cells suggested a role in cell proliferation and
tumour angiogenesis (Ornitz and Itoh, 2001). Introduction of an
FGF2 cDNA expression vector in hamster kidney fibroblasts induced
serum- and anchorage-independent growth (Neufeld et al, 1988),
demonstrating the oncogenic potential of FGF2.
Nearly 15 years ago, Schweigerer and co-workers isolated FGF2
from Ewing tumour cells. Unexpectedly, they demonstrated that
this classical growth and differentiation factor induced growth
arrest rather than proliferation in Ewing tumour cells in vitro
(Schweigerer et al, 1987). Recent investigations showed that this
growth arrest is accompanied by features characteristic of
apoptotic cell death (Sturla et al, 2000; Westwood et al, 2002).
These results led to the question how Ewing tumour cells survive
in an FGF2-containing environment in vivo? Modulation of FGF2-
induced apoptosis by potential survival signals was the primary
focus of this study. It has recently been pointed out that standard
monolayer cultures may only poorly reflect the in vivo environ-
ment of Ewing tumour cells (Lawlor et al, 2002). Only a limited
number of signalling cascades, required for tumour cell growth
and survival in vivo, are triggered. Therefore, in this study
potential survival signals, for example, integrin-mediated adhesion
or soluble growth factors, that may counteract FGF2-induced cell
death were studied under different in vitro conditions including
anchorage-independent colony and adherent monolayer cultures.
MATERIALS AND METHODS
Cell culture and chemicals
The Ewing tumour cell lines CADO-ES1 and RD-ES were
purchased from the DSMZ, Braunschweig, Germany. The TC-71
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scell line was provided by Professor TJ Triche (Whang-Peng et al,
1984). RM-82, VH-64, and WE-68 were established by one of the
authors (van Valen, 1999). All cell lines were maintained in RPMI
1640 medium (Biochrom, Berlin, Germany) containing 10% FCS,
2m ML -glutamine, 100Uml
 1 penicillin and 100mgml
 1 strepto-
mycin (all Lifetechnologies, Karlsruhe, Germany) at 371Ci na
humidified 5% CO2 atmosphere. Cells were cultured in collagen-
coated 25cm
2 tissue culture flasks (Greiner Labortechnik, Solin-
gen, Germany). All cell lines were regularly tested for mycoplasma
contamination. Lyophilised FGF2 (Sigma, Deisenhofen, Germany)
was dissolved in IMDM (Lifetechnologies) at 5mgml
 1 (aliquoted
and stored at  201C until required). TNF-related apoptosis-
inducing factor (TRAIL, PeproTech Inc., Rocky Hill, NJ, USA) was
dissolved in PBS at 50mgml
 1. The phosphoinositide 3-OH kinase
(PI3K) inhibitor LY294002 and the caspase inhibitors Ac-DEVD-
CHO, z-IETD-FMK and z-VAD-FMK (all from Calbiochem, Bad
Soden, Germany) were dissolved in DMSO at 50, 20, 10 and 20mM,
respectively.
In vitro growth assays
Anchorage-independent growth was analysed by plating Ewing
tumour cells as a single-cell suspension in semisolid medium
containing 0.9% (wv
 1) methylcellulose in IMDM, 15% FCS
(vv
 1) and 0.5% (wv
 1) BSA. For serum-free assays, cells were
plated in semisolid medium containing 0.9% methylcellulose in
IMDM, 2.5% (wv
 1) BSA and a supplement including 25mgml
 1
insulin, 50mgml
 1 transferrin, 6mgml
 1 cholesterol and
14mgml
 1 linoleic acid (all purchased from Sigma). For each
assay, 1ml of the cell suspension was plated in duplicate, triplicate
or quadruplicate into sterile 35mm Petri dishes (Nunc, Karlsruhe,
Germany) that were incubated at 371C. Colonies were counted
after 11–14 days and each experiment was repeated at least two
times.
Growth characteristics of adherent cells were investigated by
utilising the assay described by Hansen et al (1989). 2 10
4 cells
were plated in quadruplicate in 100ml of RPMI 1640, 10% FCS, L-
glutamin, penicillin and streptomycin or, for serum-free condi-
tions, in 100ml IMDM containing 2% BSA (wv
 1) and supple-
mental factors (as described above) in collagen-coated 96-well
plates (Becton Dickinson, Heidelberg, Germany). Cells were
allowed to attach for 3h at 371C with 5% CO2. Afterwards FGF2
was added. In experiments using caspase or PI3K inhibitors, these
were added 1h prior to FGF2 treatment. After different time
intervals (24–72h), 20ml of a 5mgml
 1 MTT solution (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma)
was added for 4h at 371C to each well. The media were replaced
by 100ml of lysis solution (50% (vv
 1) N,N-dimethylformamide,
20% (wv
 1) SDS) (to dissolve the formazan crystals) and plates
were read at 550nm (test wavelength) and 630nm (reference
wavelength) in a Dynatech MR 7000 microplate reader (Denken-
dorf, Germany). Each experiment was repeated at least two times.
Results are expressed as percentage of controls. The paired t-test
was performed for statistical analysis.
Detection of FGF2 protein
Crude cell lysates were obtained by resuspending 4 10
6 cells in
1ml extraction buffer (100mM Tris–HCl, pH 8.0, 0.5% Triton X-
100, 10mM EDTA). Samples were subjected to three rounds of
5min in liquid nitrogen, 5min at 371C and 5min on ice. Samples
were centrifuged, aliquoted and stored at  201C. For analysis of
FGF2 protein in crude cell lysates and supernatant, a FGF2-ELISA
(R&D, Wiesbaden-Nordenstadt, Germany) was applied.
Characterisation of cell death
Cells were grown in collagen-coated 25cm
2 tissue culture flasks
containing media and 5ngml
 1 FGF2 for up to 48h. Cells were
harvested and labelled using an annexin V-FITC apoptosis
detection kit (Pharmingen, Heidelberg, Germany). Annexin V-
positive cells were quantified by flow cytometry on a FACScan
(Becton Dickinson) using CellQuest software (Becton Dickinson).
RESULTS
Fibroblast growth factor inhibits proliferation of
clonogenic Ewing tumour cells
It has been well established that FGF2 inhibits proliferation of
Ewing tumour cell lines in vitro (Schweigerer et al, 1987; Sturla
et al, 2000; Westwood et al, 2002) though conflicting results have
recently been reported under serum-free culture conditions
(Girnita et al, 2000). To quantify this inhibitory effect of FGF2
on clonogenic tumour cells, the cell line TC-71 was plated in
methylcellulose at different concentrations of FGF2.
Under serum-free conditions, FGF2 at concentrations ranging
from 50 down to 0.5ngml
 1 (Figure 1) completely abrogated the
colony-forming ability of TC-71 cells. However, in the presence of
15% FCS, TC-71 cells were less sensitive to 0.5ngml
 1 FGF2. This
protective effect of serum could be overcome by higher
concentrations of FGF2. No stimulatory response to FGF2 at
concentrations as high as 50ngml
 1 was observed under any
conditions.
Ewing tumour cells express FGF2 as well as its receptors
Expression of FGF2 was assessed in a panel of Ewing tumour cell
lines. Fibroblast growth factor protein could be detected in crude
cell lysates from all the six cell lines, while no FGF2 protein could
be detected in the supernatant of these cells (Table 1).
In order to identify the receptor(s) that transduces the
inhibitory FGF2 signal in Ewing tumour cells, Western blot
analyses identified FGFR1, -2 protein in all cell lines, whereas
FGFR-3 protein was only detected in TC-71, VH-64 and WE-68. No
FGFR-4 protein was found despite the presence of FGFR4-mRNA
(data not shown). The Western blot results, therefore, confirm and
extend previous studies (Sturla et al, 2000) by detection of FGFR1,
-2 and -3 on the protein level in a high percentage of Ewing tumour
cell lines.
ng ml–1 FGF2
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Figure 1 Increasing concentrations of FGF2 decreased the colony-
forming potential of TC-71 cells in serum-containing (black dots) and
serum-free (white dots) colony assays. This inhibitory effect was significant
(Po0.05) for concentrations 40.5ngml
 1. Notably, 15% FCS protected
approx. 55% of the colony-forming ability of TC-71 at low concentrations
of FGF2 (0.5ngml
 1).
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accompanied by caspase-dependent apoptosis
In order to analyse the events accompanied by FGF2-induced
growth inhibition, FGF2-treated cells were studied for markers of
apoptosis. An early feature of apoptotic cells is exposure of
phosphatidyl serines on the cell surface, which are recognised by
the annexin V antibody. Consistent with published reports
(Westwood et al, 2002), an annexin V single-positive population
could be detected after 24h treatment with FGF2 (data not shown).
Caspases are essential proteases during apoptotic cell death. In
order to define whether caspases are involved in FGF2-induced
apoptosis, a panel of caspase inhibitors were applied: z-VAD-FMK
– a pan-caspase inhibitor; Ac-DEVD-CHO – primarily an inhibitor
of the effector caspase 3 and, to a lesser extent, caspase 7 and 8; z-
IETD-FMK – an inhibitor of the initiator caspase 8. As shown in
Figure 2, pre-incubation of TC-71 cells with these inhibitors did
not completely protect TC-71 cells from FGF2-induced cell death:
z-VAD rescues approx. 67% (67.1715.1%) of the cells, the caspase
3 inhibitor Ac-DEVD-CHO protects only 35% (34.8712.5%, data
not shown) of the cells from apoptosis. In contrast, the caspase 8
inhibitor as well as the pan-caspase inhibitor were able to
completely protect TC-71 cells from TRAIL-induced apotosis
(Figure 2), indicating the effectiveness of the used inhibitors. These
results confirm that FGF2-induced cell death is in part mediated
via caspase activation. Interestingly and in contrast to TRAIL-
induced apoptosis, the caspase 8 inhibitor z-IETD-FMK has no
protective effect against FGF2-induced apoptosis (Figure 2).
Adequate survival signals rescue Ewing tumour cells from
FGF2-induced apoptosis
The obtained data confirm and extend recent findings showing
that Ewing tumour cells express FGF2 and its receptors and that
extracellularly supplied FGF2 induces apoptosis (Schweigerer et al,
1987; Sturla et al, 2000; Westwood et al, 2002). This leads to the
central question how Ewing tumour cells survive and proliferate in
an FGF2-containing environment in vivo.
To address this question, Ewing tumour cell survival in the
presence of FGF2 was studied under different culture conditions.
Monolayer cultures on collagen-coated culture flasks under
defined serum-free conditions were used as a model for integrin-
mediated survival signals. Spheroid cell cultures are regarded as
suitable models for three-dimensional growth and cell–cell
interactions of in vivo tumours (Santini and Rainaldi, 1999).
Unlike the spheroid liquid-overlay cultures that allow aggregation
of tumour cells (Santini and Rainaldi, 1999; Lawlor et al, 2002), the
methylcellulose assay reads out single cells with the ability of
clonal expansion, an important feature of metastatic cells.
Two cell lines (CADO-ES1 and VH-64) were resistant to FGF2
under all culture conditions (data not shown). Four cell lines (RD-
ES, RM-82, TC-71 and WE-68) were FGF2-sensitive, but distinct
culture conditions were able to rescue these cell lines from FGF-2-
induced apoptosis. Exposure to serum alone (in the presence of
15% foetal calf serum) or integrin-mediated adhesion (serum-free
monolayer cultures on a collagen matrix), both rendered one of the
four Ewing tumour cell lines at least partially resistant to 5ngml
 1
FGF-2 (serum in RD-ES and adhesion in RM-82; Figure 3A and B).
However, integrin-mediated adhesion combined with serum
(monolayer cultures on a collagen matrix with 15% FCS) provides
a strong synergistic survival signal: under these conditions, three
out of the four cell lines are completely resistant to 5ngml
 1 FGF2
and 37.2710.3% of TC-71 cells are protected from FGF2-induced
apoptosis (Figure 3C).
Previous studies suggested insulin-like growth factor 1 (IGF1) as
one of the key growth factors of Ewing tumours (van Valen et al,
1992; Scotlandi et al, 1996, 2002). It was, therefore, investigated
whether serum-derived IGF1 may be the/one of the protective
factor/s antagonising FGF2. However, IGF1 at 0.2–20ngml
 1
neither increased the colony-forming ability and proliferative
activity of Ewing tumour cells under serum-free conditions, nor
was IGF1 sufficient to protect TC-71 cells from FGF2-induced
apoptosis (data not shown).
Phosphoinositide 3-OH kinase is involved in integrin- and
serum-mediated survival signals
The PI3K/AKT pathway is considered to be an important
signalling pathway mediating survival signals in Ewing tumour
cells. Activation of AKT leads to phosphorylation and inactivation
of proapoptotic molecules such as bad, forkhead and caspase 9,
and activation of molecules regulating cell growth and expression
of genes responsible for survival (Datta et al, 1999). Inhibition of
this signalling pathway in Ewing tumour cells with the PI3K
specific inhibitor LY294002 has been reported to enhance
apoptosis (Toretsky et al, 1999). In addition, it has been shown
that integrin signalling renders tumour cells insensitive to
apoptosis-inducing drugs (Aoudjit and Vuori, 2001) and this
resistance is also mediated by the PI3K/AKT pathway.
Table 1 Detection of FGF2 in cell lysates and supernatants in a panel of
Ewing tumour cell lines
Protein in
Cell line Supernatant pg/10
6 cells Cell lysate pg/10
6 cell
CADO-ES1 —
a 47.376.9
RD-ES — 0.7570.009
RM-82 — 20.771.1
TC-71 — 35.574.1
VH-64 — 9.270.4
WE-68 — 78.970.6
L87/4 (BM stroma) 278.3721.7 34227110
Medium (10% FCS) —
Medium (0% FCS) —
a : values obtained were below the detection limit of 10ngml
 1. % of control
0 20 40 60 80 100 120 140 160
F+z-VAD
F+z-IETD
FGF2
T+z-VAD
T+z-IETD
TRAIL
Con.
Figure 2 Both FGF2 and TRAIL inhibited proliferation of TC-71 Ewing
tumour cells in serum-free monolayer cultures by induction of apoptosis.
While TRAIL-induced apoptosis could be blocked both by the caspase 8
inhibitor z-IETD-FMK and pan-caspase inhibitor z-VAD-FMK, FGF2-induced
apoptosis was only significantly inhibited by z-VAD-FMK (Po0.005). This
indicates that the FGF2-induced death signal is not mediated via caspase 8.
Con.: untreated control; TRAIL: 50ngml
 1 TRAIL; Tþz-IETD: 25mM z-
IETD-FMK 1h before TRAIL; Tþz-VAD: 50mM of z-VAD-FMK 1h before
TRAIL; FGF2: 5ngml
 1 FGF2; Fþz-IETD: 25mM z-IETD-FMK 1h before
FGF2; Fþz-VAD: 50mM of z-VAD-FMK 1h before FGF2.
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involved in serum- and adhesion-mediated resistance to FGF2-
induced apoptosis. LY294002 is a specific PI3K inhibitor (Vlahos
et al, 1994) and its interaction with the ATP-binding pocket of
PI3K has been well characterised (Walker et al, 2000). When 80mM
LY294002 was added to serum-containing adherent monolayer
cultures, tumour cell proliferation was dramatically reduced to
approximately 40% in all four cell lines tested (Figure 4A). Under
serum-free adherent monolayer culture condition, LY294002 had
no effect on tumour cell proliferation in CADO-ES1 and TC-71
cells, but a minor inhibitory effect on RD-ES and RM-82 cells
(Figure 4A). This indicates that PI3K signalling is central in
mediating serum-related survival signals in all cell lines as well as
in mediating adhesion-related survival signals in RD-ES and RM-
82 cells.
In accordance with this assumption are the results obtained
when TC-71 and RD-ES cells were cultured in the presence of FGF2
and LY294002 under serum-containing and serum-free conditions
(Figure 4B). This combination resulted in an increased effect on
FGF2-induced apoptosis under serum-containing culture condi-
tions in TC-71 cells (Figure 4B left columns), indicating that
inhibition of the serum-triggered PI3K survival signal renders TC-
71 cells more sensitive to FGF2-induced apoptosis. A similar effect
was seen with RD-ES cells. When these cells were cultured under
serum-free conditions, the inhibition of the adhesion-triggered
PI3K survival signal resulted in sensitisation of these cells to FGF2-
induced apoptosis (Figure 4B, right columns).
These results show that PI3K signalling plays an important role
in mediating serum- and/or integrin-related survival signals in
Ewing tumour cell lines and that these survival pathways are
involved in antagonising FGF2-induced apoptosis.
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Figure 3 Comparison of the effects of 5ngml
 1 FGF2 (A) in serum-
containing (15% FCS) colony assays, (B) in serum-free adherent monolayer
cultures and (C) in serum-containing adherent monolayer cultures.
Integrin-mediated adhesion plus soluble serum factors had a strong
synergistic effect in antagonising FGF2-induced apoptosis (C). *WE-68 cells
do not grow in serum-free adherent monolayer cultures.
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Figure 4 Inhibition of PI3K with LY294002 (80mM) decreased
proliferation/growth of all Ewing tumour cell lines to approx. 38% in
serum-containing adherent cell cultures (Po0.05) (A) (left columns).
Under serum-free conditions, no significant inhibitory effect was seen with
the cell lines CADO-ES1 and TC-71 (P40.7), while RD-ES and RM-82
showed a reduction in proliferation to approx. 45% (A) (right columns).
The combination of LY294002 and FGF2 resulted in an increased sensitivity
to FGF2 in serum-containing (TC 71 cells) (B) (left columns) and in serum-
free adherent monolayer cultures (RD-ES cells) (B) (right columns)
(Po0.05). This indicates that PI3K-mediated survival signals are involved in
antagonising FGF2-induced apoptosis.
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sDISCUSSION
We were able to confirm that FGF2 has a dose-dependent growth-
inhibitory effect on most Ewing tumour cell lines in vitro and that
this growth inhibition is associated with induction of apoptosis.
However, the biological and clinical impact of expression of FGF2
and its receptors by Ewing tumour cells remains obscure.
Activation of initiator caspases in FGF2-treated cells, including
the receptor-triggered caspase 8 and lack of mitochondrial
cytochrome c release, had led to the hypothesis that FGF2-induced
apoptosis may represent a new classical receptor-induced cell
death pathway (Westwood et al, 2002). If this hypothesis is true, a
caspase 8 inhibitor would be expected to protect Ewing tumour
cells from FGF2-induced apoptosis. However, this assumption was
not supported by our experiments. Inhibition of the receptor-
associated initiator caspase 8 with z-IETD-FMK had no effect on
Ewing tumour cell survival after exposure to FGF2. The delay in
the occurrence of cell death after exposure to FGF2 indicates that
induction of apoptosis may be a secondary event mediated by an
unknown signalling cascade. Recently, it has been found out that
FGF2-induced activation of JNK may play a crucial role in
inducing apoptosis in Ewing sarcoma-related Askin tumour cells
(Kim et al, 2004).
Nevertheless, four out of six Ewing tumour cell lines in vitro die
after exposure to FGF2. In this context, it was surprising to observe
that all Ewing tumour cell lines expressed FGF2 at the RNA and
protein level (data not shown and Table 1). In contrast to L87/4
stroma cells, however, no FGF2 could be detected in the culture
medium of the Ewing tumour cell lines (Table 1). Fibroblast
growth factor lacks a secretory signal and is secreted by an
ER/Golgi-independent mechanism (Engling et al, 2002). The lack
of secretion of FGF2 under standard culture conditions may be one
of the mechanisms by which Ewing tumour cells protect
themselves from autocrine growth inhibition and induction of
apopotosis.
However, lack of secretion of FGF2 by Ewing tumour cells is
insufficient to explain formation, survival and metastasis of these
tumour cells in or to the bone marrow microenvironment, which is
a rich source of FGF2 (Brunner et al, 1993). Similar to the situation
in patients, Ewing tumours metastasise at high frequency to bone
and bone marrow in NOD/scid mice (Vormoor et al, 2001),
indicating that the bone marrow microenvironment is supportive
for growth and survival of these cells. It was, therefore,
hypothesised that this FGF2-containing microenvironment itself
is responsible for rendering Ewing tumour cells insensitive to
FGF2. The complex interaction between tumour cells and their
microenvironment and the importance of this interaction for
tumour cell survival is increasingly been recognised (Liotta and
Kohn, 2001). In this context, it has been pointed out that standard
monolayer cultures may only poorly reflect the in vivo environ-
ment of Ewing tumour cells (Lawlor et al, 2002), emphasising the
importance of culture conditions on in vitro results and their
biological significance.
Using both adherent monolayer and non-adherent colony assays
allowed dissection of important aspects of the interaction between
Ewing tumour cells and their microenvironment. Both integrin-
mediated adhesion and soluble serum factors alone provide
positive, though weak, survival signals partially antagonising
FGF2 activity. However, adhesion combined with serum had a
strong synergistic effect and caused Ewing tumour cell resistance
to FGF2-induced cell death. These latter conditions most likely
best reflect the microenvironment of human Ewing tumours in
vivo, suggesting that FGF2-induced apoptosis may be a tissue
culture artefact.
The serum as well as the adhesion signal is mediated to a large
extent by the classical PI3K signalling cascade, as could be shown
by inhibition experiments with LY294002. Phosphoinositide 3-OH
kinase is a key regulator of growth factor- and integrin-related
survival signals and the role of its downstream target, the kinase
AKT, has been well established in preventing apoptosis and
supporting survival of many cell types (Datta et al, 1999; Danen
and Yamada, 2001). However, it remains to be identified which
soluble growth factors are responsible for this serum effect. The
serum effect could not be attributed to IGF1, a growth factor
thought to be one of the key mitogenic and survival factors in
Ewing tumours. In addition, the resistance of Ewing tumour cells
to imatinib mesylate, an inhibitor of c-KIT (Hotfilder et al, 2002),
suggests that stem cell factor is also not a key survival factor in
Ewing tumours.
Although it could be demonstrated that Ewing tumour cells
escape FGF2-induced apoptosis through microenvironment-
mediated survival signals, the biological function of FGF2
expression in Ewing tumour cells remains unknown. Under
serum-free conditions, FGF2 has been shown to be a potent
inducer of EWS/FLI1 protein expression and by this mechanism
may stabilise the malignant phenotype (Girnita et al, 2000).
Alternatively, FGF2 may be released under hypoxic stress as a
potent angiogenic factor; it may affect bone remodelling and thus
tumour progression by osteoclast recruitment (Collin-Osdoby et al,
2002), or it may act in a paracrine fashion by inducing growth
factor production in bone marrow stroma cells (Zhang et al, 2002;
Bisping et al, 2003).
In conclusion, although the biological function of FGF2
expression remains to be defined, several mechanisms could be
identified by which Ewing tumour cells escape the detrimental
effects of FGF2. These include the absence of FGF2 secretion under
standard conditions and the modulation of inhibitory FGF2
signalling pathways by survival signals provided from integrin-
dependent adhesion and soluble serum factors. The PI3K/AKT
pathway is a key pathway involved in mediating the survival
signals.
These survival signals need further investigation as they can be
expected to play a central role in resistance to other apoptosis-
inducing agents including chemotherapeutic drugs (Aoudjit and
Vuori, 2001) and will help to understand how Ewing tumour cells
survive under sometimes hostile conditions in vivo. A better
understanding of these survival signals will facilitate the develop-
ment of treatments more specifically targeted against the tumour
cells.
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